Dr Megan Crumbaker

Role: Clinical Research Fellow

Selected publications

See all publications

2025
European Urology Focus10.1016/j.euf.2025.03.017
Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants.
Mitchell G Lawrence, Shivakumar Keerthikumar, Scott L Townley, Ashlee K Clark, Georgia B Cuffe, Geraldine Laven-Law, Adrienne R Hanson, Raj K Shrestha, Todd P Knutson, Michelle G Richards, Linda Teng, Nicholas Choo, Megan Crumbaker, Anthony M Joshua, Eva Corey, Peter S Nelson, Scott M Dehm, Gail P Risbridger, Wayne D Tilley, Theresa E Hickey, Renea A Taylor, Luke A Selth
2025
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine10.2967/jnumed.124.269252
Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.
Louise Kostos, James P Buteau, Grace Kong, Ben Tran, Mohammad B Haskali, Michael Fahey, Megan Crumbaker, Louise Emmett, Michael S Hofman, Arun A Azad
2025
The Lancet. Oncology10.1016/S1470-2045(25)00009-9
Overall survival and quality of life with [Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Anthony M Joshua, Shahneen Sandhu, Andrew Nguyen, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J Francis, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Craig Gedye, Natalie K Rutherford, Aravind S Ravi Kumar, David Pook, Shakher Ramdave, David P Nadebaum, Mark Voskoboynik, Andrew D Redfern, William Macdonald, Laurence Krieger, Geoff Schembri, Wei Chua, Peter Lin, Lisa Horvath, Patricia Bastick, Patrick Butler, Alison Yan Zhang, Margaret McJannett, Hayley Thomas, Ailsa Langford, Michael S Hofman, Andrew James Martin, Ian D Davis, Martin R Stockler, ,
2024
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine10.2967/jnumed.124.267606
Comparison of Posttherapy 4- and 24-Hour [Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.
Mina Swiha, Sarennya Pathmanandavel, Nathan Papa, Zahra Sabahi, Sherrington Li, Alex Zheng, Sobia Khan, Maria Ayers, Shikha Sharma, Megan Crumbaker, Andrew Nguyen, Lyn Chan, Narjess Ayati, Louise Emmett
2024
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine10.2967/jnumed.124.267881
Utility of Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on Ga-PSMA-11 PET/CT.
Sherrington Li, Andrew Nguyen, William Counter, Nikeith C John, Jeremiah De Leon, George Hruby, Anthony M Joshua, Phillip Stricker, Megan Crumbaker, Narjess Ayati, Lyn Chan, Zahra Sabahi, Mina Swiha, Andrew Kneebone, Keith Wong, Victor Liu, Shikha Sharma, Shikha Agrawal, Louise M Emmett

See all Garvan publications

Explore our research

Our impact

Our people

News and resources

About us

Support Us

Dr Megan Crumbaker

Selected publications

Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants.

Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer.

Overall survival and quality of life with [Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial.

Comparison of Posttherapy 4- and 24-Hour [Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.

Utility of Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on Ga-PSMA-11 PET/CT.